Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HCC
MCID: HPT023
MIFTS: 100

Hepatocellular Carcinoma (HCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatocellular Carcinoma

About this section

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 56 12 74 58 73 36 29 54 6 15 37 17
Liver Cancer 56 12 73 42 15
Primary Liver Cancer 12 52 15
Liver Neoplasms 74 43 71
Hepatoma 56 12 73
Hcc 56 58 73
Rare Tumor of Liver and Intrahepatic Biliary Tract 52 58
Primary Malignant Neoplasm of Liver 12 71
Malignant Neoplasm of Liver 12 71
Hepatoblastoma, Somatic 56 13
Cancer, Hepatocellular 56 39
Liver Cell Carcinoma 56 73
Hepatic Cancer 12 54
Hepatoblastoma 58 71
Lcc 56 73
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Hepatocellular Carcinoma, Childhood Type, Somatic 56
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 71
Resectable Malignant Neoplasm of the Liver 12
Childhood-Onset Hepatocellular Carcinoma 58
Adult Primary Hepatocellular Carcinoma 71
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Pediatric Hepatocellular Carcinoma 58
Hepatocellular Carcinoma, Somatic 56
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 52
Malignant Hepatobiliary Neoplasm 71
Hepatocellular Cancer, Somatic 56
Adult Hepatocellular Carcinoma 58
Rare Tumor of Liver and Ibt 58
Primary Tumor of the Liver 52
Liver Cell Carcinoma; Lcc 56
Carcinoma, Hepatocellular 43
Malignant Tumor of Liver 12
Primary Cancer of Liver 52
Primary Liver Carcinoma 52
Hepatocellular Cancer 73
Neoplasm of the Liver 6
Childhood-Onset Hcc 58
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 71
Liver Neoplasm 17
Pediatric Hcc 58
Adult Hcc 58
Hepatomas 15

Characteristics:

Orphanet epidemiological data:

58
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;
adult hepatocellular carcinoma
Inheritance: Not applicable;
pediatric hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adolescent,Childhood; Age of death: adolescent,adult,early childhood,late childhood,young Adult;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

31
hepatocellular carcinoma:
Inheritance autosomal dominant inheritance somatic mutation heterogeneous


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare hepatic diseases


Sources

Summaries for Hepatocellular Carcinoma

About this section
MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to colorectal cancer and gastric cancer, and has symptoms including fever, nausea and vomiting and abdominal pain. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Pravastatin and Tegafur have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and lung, and related phenotypes are hepatomegaly and portal hypertension

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes and located in the liver.

OMIM : 56 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

KEGG : 36 Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and one of the rare human neoplasms etiologically linked to viral factors. It has been shown that, after HBV/HCV infection and alcohol or aflatoxin B1 exposure, genetic and epigenetic changes occur. The recurrent mutated genes were found to be highly enriched in multiple key driver signaling processes, including telomere maintenance, TP53, cell cycle regulation, the Wnt/beta-catenin pathway (CTNNB1 and AXIN1), the phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Recent studies using whole-exome sequencing have revealed recurrent mutations in new driver genes involved in the chromatin remodelling (ARID1A and ARID2) and the oxidative stress (NFE2L2) pathways.

UniProtKB/Swiss-Prot : 73 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 74 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Sources

Related Diseases for Hepatocellular Carcinoma

About this section

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1670)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer 35.3 TP53 TERT PIK3CA PDGFRL NRAS NFE2L2
2 gastric cancer 35.2 TP53 TERT PIK3CA NRAS NFE2L2 MIR34A
3 breast cancer 35.1 TP53 TERT PIK3CA NRAS MIR34A MIR221
4 lung cancer 34.5 TP53 TERT PIK3CA NRAS NFE2L2 MIR34A
5 lung cancer susceptibility 3 34.5 TP53 TERT PIK3CA NRAS NFE2L2 MIR21
6 cholangiocarcinoma 34.4 TP53 TERT PIK3CA MIR21 MET KRAS
7 prostate cancer 34.4 TP53 TERT PIK3CA NFE2L2 MIR34A MIR221
8 pancreatic cancer 34.3 TP53 TERT PIK3CA MIR34A MIR221 MIR21
9 ovarian cancer 34.2 TP53 TERT PIK3CA MIR34A MIR221 MIR21
10 melanoma 34.1 TP53 TERT PIK3CA NRAS MIR34A MIR221
11 glioblastoma multiforme 34.1 TP53 TERT PIK3CA NRAS MIR221 MIR21
12 leukemia, acute myeloid 34.1 TP53 TERT PIK3CA NRAS MIR34A MIR221
13 hepatitis b 34.0 TP53 PIK3CA MIR21 MIR17 KRAS
14 bladder cancer 34.0 TP53 TERT PIK3CA NRAS MIR34A MIR221
15 neuroblastoma 34.0 TP53 TERT PIK3CA NRAS NFE2L2 MIR34A
16 esophageal cancer 33.9 TP53 TERT PIK3CA MIR34A MIR21 KRAS
17 renal cell carcinoma, nonpapillary 33.8 TP53 PIK3CA NRAS MIR34A MIR221 MIR21
18 pancreatic adenocarcinoma 33.8 TP53 TERT PIK3CA MIR221 MIR21 MET
19 adenocarcinoma 33.8 TP53 PIK3CA MET KRAS HRAS FGFR1
20 intrahepatic cholangiocarcinoma 33.6 TP53 KRAS CTNNB1 APC
21 gastric adenocarcinoma 33.5 TP53 TERT PIK3CA NRAS MET KRAS
22 adenoma 33.5 TP53 PIK3CA KRAS CTNNB1 APC
23 endometrial cancer 33.4 TP53 TERT PIK3CA NRAS MIR34A KRAS
24 cervical cancer 33.4 TP53 TERT PIK3CA NFE2L2 MIR34A MIR21
25 non-alcoholic steatohepatitis 33.4 TP53 MIR34A MIR21 MIR122
26 medulloblastoma 33.4 TP53 TERT PIK3CA NRAS MIR34A MIR17
27 leukemia, chronic lymphocytic 33.4 TP53 PIK3CA NRAS MIR34A MIR221 MIR21
28 sarcoma 33.4 TP53 PIK3CA NRAS MET KRAS HRAS
29 myeloma, multiple 33.4 TP53 NRAS MIR21 MIR17 MET KRAS
30 acute promyelocytic leukemia 33.3 TP53 TERT PIK3CA NRAS NFE2L2 MIR221
31 nasopharyngeal carcinoma 33.3 TP53 TERT PIK3CA NRAS MIR21 MIR17
32 lymphoma, non-hodgkin, familial 33.3 TP53 PIK3CA NRAS MIR34A MIR21 MIR17
33 body mass index quantitative trait locus 11 33.2 TP53 MIR34A MIR221 MIR21 MIR17 MIR122
34 hepatoblastoma 33.2 TP53 MET CTNNB1 APC
35 b-cell lymphoma 33.1 TP53 MIR34A MIR21 MIR17 CASP8
36 familial adenomatous polyposis 33.0 TP53 KRAS HRAS CTNNB1 AXIN1 APC
37 kidney cancer 33.0 TP53 PIK3CA NFE2L2 MIR21 MIR17 MIR122
38 lymphoma 33.0 TP53 PIK3CA NRAS MET FGFR1 CASP8
39 bile duct cancer 33.0 TP53 MIR21 MIR17 MET KRAS HRAS
40 brain cancer 33.0 TP53 TERT PIK3CA NRAS MIR21 MIR17
41 glioma 33.0 TP53 PIK3CA MIR34A MIR221 MIR21 MIR17
42 clear cell renal cell carcinoma 32.9 TP53 TERT MIR221 MIR21 MIR122 MET
43 colon adenocarcinoma 32.9 TP53 PIK3CA NRAS MIR21 KRAS CTNNB1
44 leukemia, acute lymphoblastic 32.9 TP53 MIR221 MIR21 MIR17 KRAS HRAS
45 squamous cell carcinoma 32.8 TP53 PIK3CA NFE2L2 HRAS CTNNB1
46 bladder urothelial carcinoma 32.8 TP53 TERT PIK3CA NRAS NFE2L2 KRAS
47 leukemia 32.8 TP53 TERT NRAS KRAS HRAS FGFR1
48 oral squamous cell carcinoma 32.7 TP53 MIR34A MIR221 MIR21 MIR17 MIR122
49 gallbladder cancer 32.7 TP53 TERT PIK3CA KRAS CTNNB1
50 colorectal adenocarcinoma 32.7 TP53 KRAS HRAS CTNNB1 APC

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma
Sources

Symptoms & Phenotypes for Hepatocellular Carcinoma

About this section

Human phenotypes related to Hepatocellular Carcinoma:

58 31 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002240
2 portal hypertension 58 31 hallmark (90%) Very frequent (99-80%) HP:0001409
3 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002027
4 hyperbilirubinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002904
5 hypoalbuminemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003073
6 type ii diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0005978
7 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
8 abnormality of the rectum 58 31 frequent (33%) Frequent (79-30%) HP:0002034
9 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
10 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
11 esophageal varix 58 31 frequent (33%) Frequent (79-30%) HP:0002040
12 venous insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0005293
13 abdominal distention 58 31 frequent (33%) Frequent (79-30%) HP:0003270
14 epigastric pain 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0410019
15 hypokalemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002900
16 fatigue 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0012378
17 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
18 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
19 hypoglycemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001943
20 anemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001903
21 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
22 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
23 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
24 neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0002664
25 hyponatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002902
26 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
27 internal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0011029
28 polycythemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001901
29 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
30 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
31 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
32 poor appetite 58 31 occasional (7.5%) Occasional (29-5%) HP:0004396
33 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
34 metabolic alkalosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0200114
35 mood changes 58 31 occasional (7.5%) Occasional (29-5%) HP:0001575
36 hepatic encephalopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002480
37 hepatic necrosis 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0002605
38 anasarca 58 31 occasional (7.5%) Occasional (29-5%) HP:0012050
39 hemobilia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100762
40 liver abscess 58 31 very rare (1%) Very rare (<4-1%) HP:0100523
41 hypotension 58 31 very rare (1%) Very rare (<4-1%) HP:0002615
42 budd-chiari syndrome 58 31 very rare (1%) Very rare (<4-1%) HP:0002639
43 vomiting 58 Frequent (79-30%)
44 hepatic fibrosis 58 Very frequent (99-80%)
45 abnormality of the liver 58 Very frequent (99-80%)
46 elevated alpha-fetoprotein 58 Very frequent (99-80%)
47 hepatocellular carcinoma 31 HP:0001402
48 abnormality of the hepatic vasculature 58 Very frequent (99-80%)
49 portal vein thrombosis 58 Frequent (79-30%)
50 abnormality of glycoprotein metabolism 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM:

56
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer

Clinical features from OMIM:

114550

UMLS symptoms related to Hepatocellular Carcinoma:


fever, nausea and vomiting, abdominal pain, constipation, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.05 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.05 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.05 KRAS
4 Decreased viability GR00106-A-0 10.05 KRAS
5 Decreased viability GR00221-A-1 10.05 FGFR1 HRAS KRAS NRAS PDGFRL PIK3CA
6 Decreased viability GR00221-A-2 10.05 FGFR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.05 HRAS NRAS
8 Decreased viability GR00221-A-4 10.05 PIK3CA
9 Decreased viability GR00301-A 10.05 KRAS
10 Decreased viability GR00381-A-1 10.05 KRAS
11 Decreased viability GR00386-A-1 10.05 FGFR1
12 Decreased viability GR00402-S-2 10.05 PIK3CA
13 Decreased cell migration GR00055-A-1 9.55 MET
14 Decreased cell migration GR00055-A-3 9.55 HRAS PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.4 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.4 APC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.4 IGF2R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.4 IGF2R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.4 APC
20 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.4 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.4 IGF2R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.4 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.4 CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.4 IGF2R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.4 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.4 KRAS

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
2 cellular MP:0005384 10.41 APC AXIN1 CASP8 CTNNB1 FGFR1 IGF2R
3 growth/size/body region MP:0005378 10.4 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
4 behavior/neurological MP:0005386 10.39 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
5 embryo MP:0005380 10.35 APC AXIN1 CASP8 CTNNB1 FGFR1 IGF2R
6 endocrine/exocrine gland MP:0005379 10.35 APC CASP8 CTNNB1 FGFR1 HRAS IGF2R
7 homeostasis/metabolism MP:0005376 10.35 APC CASP8 CTNNB1 FGFR1 HRAS IGF2R
8 craniofacial MP:0005382 10.33 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
9 digestive/alimentary MP:0005381 10.32 APC AXIN1 CTNNB1 FGFR1 HRAS KRAS
10 mortality/aging MP:0010768 10.3 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
11 immune system MP:0005387 10.26 APC CASP8 CTNNB1 FGFR1 KRAS MET
12 integument MP:0010771 10.21 APC CASP8 CTNNB1 FGFR1 HRAS KRAS
13 liver/biliary system MP:0005370 10.18 APC CASP8 CTNNB1 IGF2R KRAS MET
14 nervous system MP:0003631 10.18 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
15 limbs/digits/tail MP:0005371 10.15 APC AXIN1 CTNNB1 FGFR1 IGF2R KRAS
16 neoplasm MP:0002006 10.14 APC CASP8 CTNNB1 HRAS KRAS MET
17 muscle MP:0005369 10.03 APC CASP8 CTNNB1 FGFR1 KRAS MET
18 normal MP:0002873 10.03 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
19 hearing/vestibular/ear MP:0005377 10.02 APC AXIN1 CTNNB1 FGFR1 KRAS TP53
20 no phenotypic analysis MP:0003012 9.92 CTNNB1 FGFR1 HRAS KRAS MET NRAS
21 renal/urinary system MP:0005367 9.9 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
22 respiratory system MP:0005388 9.65 AXIN1 CASP8 CTNNB1 HRAS IGF2R KRAS
23 skeleton MP:0005390 9.4 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
Sources

Drugs & Therapeutics for Hepatocellular Carcinoma

About this section

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 716)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Tegafur Approved, Investigational Phase 4 17902-23-7 5386
3
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
4
acetic acid Approved Phase 4 64-19-7 176
5
Desflurane Approved Phase 4 57041-67-5 42113
6
Cefazolin Approved Phase 4 25953-19-9 656510 33255
7
Nadolol Approved Phase 4 42200-33-9 39147
8
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
9
Ethanol Approved Phase 4 64-17-5 702
10
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
11
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
12
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
13
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
14
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
15
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
16
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
19
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
22
Pantoprazole Approved Phase 4 102625-70-7 4679
23
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
24
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
25
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
26
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
27
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
28
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
29
Povidone Approved Phase 4 9003-39-8
30
Povidone-iodine Approved Phase 4 25655-41-8
31
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
32
Lenograstim Approved, Investigational Phase 4 135968-09-1
33 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
34
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
35
Pentetic acid Approved Phase 4 67-43-6
36
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
37
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
38
Norepinephrine Approved Phase 4 51-41-2 439260
39
Nitric Oxide Approved Phase 4 10102-43-9 145068
40
Acetaminophen Approved Phase 4 103-90-2 1983
41
Propranolol Approved, Investigational Phase 4 525-66-6 4946
42
Nicotine Approved Phase 4 54-11-5 942 89594
43
Methadone Approved Phase 4 76-99-3 4095
44
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
45
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
46
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
47
Cobicistat Approved Phase 4 1004316-88-4
48
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
49
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
50
Azathioprine Approved Phase 4 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 3245)
# Name Status NCT ID Phase Drugs
1 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
2 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
3 An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Unknown status NCT02557503 Phase 4 Oxaliplatin and fluorouracil
4 Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
5 The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy Unknown status NCT01102335 Phase 4 Telbivudine
6 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
7 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
8 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
9 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
10 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial Unknown status NCT01350206 Phase 4
11 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
12 Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus Electrode and No-touch Technique: Preliminary Study Unknown status NCT02832882 Phase 4
13 Radiofrequency Ablation Using Dual Cooled-Wet Electrode for Small Hepatocellular Carcinoma With No-touch Technique: Preliminary Study Unknown status NCT02806076 Phase 4
14 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
15 Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial Unknown status NCT02399033 Phase 4 Xihuang Capsules
16 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection Unknown status NCT03253250 Phase 4 ETVï¼›TDFï¼›ADV;Peginterferon Alfa-2a
17 A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma Unknown status NCT01997957 Phase 4 S-1
18 Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China Unknown status NCT02631499 Phase 4 Epirubicin;lipiodol
19 Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC Unknown status NCT02525380 Phase 4
20 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
21 A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
22 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
23 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
24 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
25 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
26 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
27 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
28 Improving Cone-beam Computed Tomography for Image Guided Stereotactic Body Radiation Therapy of the Liver Using Gadoxetate Disodium Unknown status NCT03215355 Phase 4 Primovist
29 Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial Unknown status NCT01351194 Phase 4
30 Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
31 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin
32 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
33 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
34 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
35 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
36 Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
37 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
38 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
39 Cholestatic Drug-induced Liver Injury: Correlation With Genotypes of UGT1A1 and 1A7, and Treatment Effect of Ursodeoxycholic Acid Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
40 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
41 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
42 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
43 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
44 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
45 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
46 Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues Unknown status NCT02982837 Phase 4 PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
47 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
48 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
49 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
50 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
regorafenib
sorafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: liver neoplasms

Sources

Genetic Tests for Hepatocellular Carcinoma

About this section

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53
Sources

Anatomical Context for Hepatocellular Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatocellular Carcinoma:

19
Liver

MalaCards organs/tissues related to Hepatocellular Carcinoma:

40
Liver, T Cells, Lung, Testes, Endothelial, Breast, Bone
Sources

Publications for Hepatocellular Carcinoma

About this section

Articles related to Hepatocellular Carcinoma:

(showing 49230, show less)
# Title Authors PMID Year
1
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 56 6 54
15608678 2005
2
MicroRNA expression, survival, and response to interferon in liver cancer. 61 46 56
19812400 2009
3
Somatic mutations of the APC gene in sporadic hepatoblastomas. 6 56
8764128 1996
4
Inducing and exploiting vulnerabilities for the treatment of liver cancer. 56 61
31578521 2019
5
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. 56 61
30814741 2019
6
Necroptosis microenvironment directs lineage commitment in liver cancer. 56 61
30209397 2018
7
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. 56 61
24578576 2014
8
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
24047069 2013
9
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
24047070 2013
10
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 56 61
24047071 2013
11
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 61 56
23758232 2013
12
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. 61 56
22922871 2012
13
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. 61 56
21822264 2011
14
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. 56 61
21499248 2011
15
Diet-induced hepatocellular carcinoma in genetically predisposed mice. 56 61
19454484 2009
16
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. 61 56
19221438 2009
17
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. 56 61
18167406 2008
18
Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. 56 61
12668613 2003
19
Molecular pathogenesis of human hepatocellular carcinoma. 56 61
12149612 2002
20
Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. 54 56
10779553 2000
21
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 6 54
10700176 2000
22
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. 54 6
10435629 1999
23
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. 56 61
9589695 1998
24
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. 54 56
7892276 1995
25
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 54 6
1849234 1991
26
Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. 56 61
2573067 1989
27
Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer. 61 56
2847975 1988
28
Fraternal hepatocellular carcinoma in young children in two families. 61 56
6321015 1984
29
Familial hepatocellular carcinoma in an endemic area of Thailand. 56 61
6317164 1984
30
Primary hepatocellular carcinoma in three male siblings. 56 61
4298178 1968
31
FRATERNAL PRIMARY HEPATOCELLULAR CARCINOMA IN THREE MALE, ADULT SIBLINGS. 61 56
14320698 1965
32
Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma. 42 61
32437694 2020
33
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
34
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
35
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
36
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
37
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
38
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. 61 46
20924108 2010
39
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. 46 61
20842113 2010
40
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. 56
20676096 2010
41
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. 46 61
19843643 2010
42
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. 46 61
20041405 2010
43
MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. 46 61
20103675 2010
44
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. 56
19762333 2009
45
MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. 61 46
19863192 2009
46
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. 61 46
19726678 2009
47
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. 46 61
19711427 2009
48
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. 46 61
19617899 2009
49
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 46 61
19671867 2009
50
Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. 46 61
19473441 2009
51
Identification of genes conferring resistance to 5-fluorouracil. 56
19622726 2009
52
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. 46 61
19585654 2009
53
MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. 46 61
19441017 2009
54
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. 54 46
19584283 2009
55
Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. 46 61
19486339 2009
56
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. 54 46
19490101 2009
57
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. 54 46
19006648 2009
58
A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. 61 46
18711148 2008
59
miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. 61 46
18692484 2008
60
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 46 61
18521080 2008
61
Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. 46 61
18508316 2008
62
MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. 46 61
18555017 2008
63
Identification of metastasis-related microRNAs in hepatocellular carcinoma. 61 46
18176954 2008
64
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 6
17673550 2007
65
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 54 46
17616664 2007
66
Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. 56
17259306 2007
67
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. 46 61
16331254 2006
68
Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. 6
15531912 2005
69
Mutation of the PIK3CA gene in ovarian and breast cancer. 6
15520168 2004
70
High frequency of mutations of the PIK3CA gene in human cancers. 6
15016963 2004
71
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. 56
12640447 2003
72
Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. 56
12101426 2002
73
Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. 6
11466687 2001
74
A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. 6
10655994 1999
75
Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. 6
10398436 1999
76
A common human skin tumour is caused by activating mutations in beta-catenin. 6
10192393 1999
77
Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. 6
9927029 1999
78
Imprinting of the mouse Igf2r gene depends on an intronic CpG island. 6
9722161 1998
79
Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. 6
9500465 1998
80
Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. 6
7898930 1995
81
Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). 6
8401536 1993
82
Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. 6
1565143 1992
83
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 6
1349102 1992
84
Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. 56
1648308 1991
85
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. 6
1672732 1991
86
Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. 56
2845134 1988
87
Rearrangement of a common cellular DNA domain on chromosome 4 in human primary liver tumors. 56
2826820 1988
88
Identification of a chromosomal aberration associated with a hepatitis B DNA integration site in human cells. 56
2830013 1988
89
Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. 56
2904349 1988
90
Type 1a glycogen storage disease with hepatoblastoma in siblings. 56
3030527 1987
91
Sequences which flank an 11p deletion observed in an hepatocellular carcinoma map to 11p13. 56
3026949 1987
92
Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. 56
2996131 1985
93
Hepatoblastoma in infant sister and brother. 56
194674 1977
94
Familial hepatoma with hepatitis-associated antigen. 56
4324021 1971
95
Hepatoblastoma in infant sisters. 56
4311111 1969
96
Cancers Metastatic to the Liver. 42
32402300 2020
97
Decision making process in simultaneous laparoscopic resection of colorectal cancer and liver metastases. Review of literature. 42
32490901 2020
98
Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. 54 61
20394499 2010
99
JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. 54 61
20525557 2010
100
The identification of stem cells in human liver diseases and hepatocellular carcinoma. 61 54
20080086 2010
101
Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. 61 54
20512928 2010
102
Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. 46
20188135 2010
103
Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. 54 61
20209613 2010
104
Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. 61 54
20144681 2010
105
Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. 61 54
20190814 2010
106
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. 54 61
20347502 2010
107
[The expression of integrin beta 1 in normal hepatic tissues, hepatic cirrhosis tissues and hepatocellular carcinoma]. 61 54
20510000 2010
108
[The relationship between FHIT and WWOX expression and clinicopathological features in hepatocellular carcinoma]. 54 61
20510001 2010
109
Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. 61 54
20440771 2010
110
Forced expression of methionine adenosyltransferase 1A in human hepatoma cells suppresses in vivo tumorigenicity in mice. 54 61
20363925 2010
111
Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. 61 54
20038433 2010
112
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. 61 54
20455578 2010
113
[Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma]. 54 61
20368117 2010
114
[Expression of SOX4 gene and early recurrence of hepatocellular carcinoma: their relationship and the clinical significance]. 61 54
20423819 2010
115
Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. 54 61
20204280 2010
116
Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. 61 54
20070393 2010
117
Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. 54 61
20198346 2010
118
Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. 54 61
19834740 2010
119
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. 54 61
19685055 2010
120
Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. 54 61
20346216 2010
121
[Effects of differentially expressed proteins in hepatocellular carcinoma cell treated by different telomerase inhibitors]. 61 54
20459048 2010
122
Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. 61 54
20331903 2010
123
Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. 61 54
20209638 2010
124
Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma. 61 54
20403046 2010
125
Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. 61 54
20356387 2010
126
[The effect of allogenic hematopoietic stem cell transplantation on tumor recurrence and metastasis of hepatocellular carcinoma after hepatectomy and the relationship with presence of AFP mRNA and VEGF-C mRNA in peripheral blood]. 54 61
20506647 2010
127
High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. 54 61
19728335 2010
128
Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. 61 54
20200618 2010
129
AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma. 54 61
20132171 2010
130
CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. 61 54
20332458 2010
131
Polymorphisms in antioxidant defence genes and susceptibility to hepatocellular carcinoma in a Moroccan population. 61 54
19929244 2010
132
FAK is involved in invasion and metastasis of hepatocellular carcinoma. 54 61
20180147 2010
133
Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. 61 54
20305761 2010
134
The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. 54 61
19956849 2010
135
Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. 61 54
20035770 2010
136
Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. 54 61
20038795 2010
137
Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. 54 61
20467490 2010
138
Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. 61 54
19897486 2010
139
Grp78 promotes the invasion of hepatocellular carcinoma. 61 54
20082722 2010
140
Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. 54 61
20008139 2010
141
RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. 61 54
19800882 2010
142
[Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues]. 54 61
20128976 2010
143
[Association between aldehyde dehydrogenase-2/cytochrome P450 2E1 genetic polymorphism and habit of alcohol drinking and the susceptibility of hepatocellular carcinoma]. 61 54
20364586 2010
144
Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. 61 54
19885616 2009
145
LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. 61 54
19843073 2009
146
Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. 61 54
19885547 2009
147
Infrequent amplification of JUN in hepatocellular carcinoma. 54 61
20044606 2009
148
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. 54 61
20014456 2009
149
Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. 54 61
19501032 2009
150
The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. 54 61
19404778 2009
151
Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. 61 54
19838081 2009
152
Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. 54 61
19885563 2009
153
GLUT1 as a therapeutic target in hepatocellular carcinoma. 54 61
19874261 2009
154
Hyperalbuminemia associated with hepatocellular carcinoma in a dog. 54 61
19473332 2009
155
JNK1, a potential therapeutic target for hepatocellular carcinoma. 61 54
19591900 2009
156
Combined hepatocellular carcinoma and osteoclast-like giant cell tumor of the liver: possible clue to histogenesis. 54 61
19883433 2009
157
SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. 61 54
19686743 2009
158
Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/- mice. 54 61
19671058 2009
159
Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. 54 61
19626374 2009
160
A novel immunotherapy to hepatocellular carcinoma: CD40-activated B lymphocytes transfected with AFPmRNA. 54 61
19632790 2009
161
Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. 54 61
19520494 2009
162
Association of p53 with Bid induces cell death in response to etoposide treatment in hepatocellular carcinoma. 54 61
20025574 2009
163
Induction of the phase II detoxification enzyme NQO1 in hepatocarcinoma cells by lignans from the fruit of Schisandra chinensis through nuclear accumulation of Nrf2. 61 54
19452436 2009
164
Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. 54 61
19585652 2009
165
Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. 61 54
19626651 2009
166
Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. 54 61
19688691 2009
167
Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. 54 61
19724899 2009
168
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. 54 61
19849855 2009
169
[VIGILIN involves in regulation of imprinting gene IGF2 and H19 in human hepatocellular carcinoma cell]. 54 61
19950580 2009
170
Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. 61 54
19639168 2009
171
Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma. 54 61
19169879 2009
172
Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. 61 54
19783881 2009
173
[Relationship between DNA methylation and expressions of p57kip2 in hepatocellular carcinoma]. 54 61
19785964 2009
174
Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. 54 61
19778454 2009
175
[Effect of 5-Aza-dC on FHIT gene expression in hepatocellular carcinoma cell line HepG2]. 61 54
19728916 2009
176
Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. 54 61
19690140 2009
177
Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. 54 61
19386347 2009
178
Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. 61 54
19617819 2009
179
Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. 61 54
19465161 2009
180
Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. 46
19472311 2009
181
Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. 54 61
19666408 2009
182
Predeposit autologous plasma donation in liver resection for hepatocellular carcinoma: toward allogenic blood-free operations.